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Abstract
Background: Phage therapy is the therapeutic use of bacteriophages to treat highly drug resistant bacterial
infections. The current surge in bacteriophage therapy is motivated mainly because of the emergence of antibiotic-
resistant bacteria in clinics. This study evaluated the therapeutic potential of three bacteriophages isolated against
Escherichia coli ec311, Klebsiella pneumoniae kp235 and Enterobacter cloacae el140 strains using Galleria mellonella.
The in vitro activity of three different phages belonging to Podoviridae and Myoviridae families was studied by the
double agar overlay method against multi-drug resistant strains. Larval survivability studies were performed to
evaluate the potential of phages against infection using G. mellonella.
Results: All the three phages were found to have potential to infect the host bacterial strains. For in vivo studies it
was observed that E. coli and E. cloacae infected larvae, should be treated with three phage doses (20 μL, 104 PFU/mL)
at 6 h interval to achieve 100% survival rate. But in the case of K. pneumoniae, a single phage dose treatment showed
promising outcome. When mixed bacterial infections (all three bacterial cultures at 108 CFU/mL) were tested, minimum
of four doses of phage cocktail (three phages) at 6 h interval was necessary to recover the larvae. All the results were
confirmed by enumerating bacteria from the larvae.
Conclusion: Our data shows that although in vitro studies showed high infectivity of phages, for in vivo models
multiple phage doses were required for effective treatment.
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Background
Antibiotics are considered as a “miracle drugs” to treat
bacterial infections but due to the cheaper availability of
antibiotics, the use of antibiotics has become common
and widespread throughout the world [1]. The irrational
and uncontrolled use of antibiotics leads to bacterial
resistance, which is of major concern to combat serious
life threatening bacterial infections [1, 2]. Escherichia
coli, Klebsiella pneumoniae and Enterobacter cloacae are
Gram-negative bacilli which fall in the ESKAPE
(Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa, and Enterobacter species) group of patho-
gens and cause serious community or hospital acquired
infections [3]. Bacteria becoming resistant to last resort
of antibiotics such as carbapenems and colistin make
clinical treatment options for infections very limited [4].
Multi-drug resistance among Enterobacteriaceae is
growing at a faster rate than once believed, which results
in high mortality rate globally [4]. In order to overcome
this problem of resistance a more effective alternative
therapeutic option is required. As bacteriophages are
very good bio-agents which feed on bacteria, they are
considered as a potential alternative to control the
bacterial multiplication in the environment as well as in
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infections [5, 6]. Phage therapy involves the use of bacte-
riophages for the treatment of bacterial infections and
has gained a renewed interest because of antibiotic
resistance in bacteria [7–9]. For in vivo studies, murine
models are one of the commonly used animal models
for studying bacterial infections and phage therapy [10].
G. mellonella, a larger wax moth larva has been found
to be a useful model to study the pathogenesis of bacter-
ial infections and to study the efficacy of antibacterial
drugs [11]. Additionally, G. mellonella is an ideal model
because they do not require ethical approval, have
shorter life span, can be grown at 37 °C and they have
similarities to vertebrates innate immune responses [12].
In earlier studies, G. mellonella has been successfully
used to evaluate the effectiveness of experimental phage
therapy [10]. In this study, we examined the in vivo
therapeutic efficiency of three bacteriophages; Escheri-
chia phage ECP311 (ECP311), Klebsiella phage KPP235
(KPP235) and Enterobacter phage ELP140 (ELP140)
against E. coli, K. pneumoniae and E. cloacae strains,
using G. mellonella as a model organism. We investi-
gated the effective dosage of target phages required to
reduce the lethality of bacterial infections in G. mello-
nella model and evaluated the dose dependent potential
of phage cocktail (three phages each at 104 PFU/mL) to
target multiple bacterial infection.
Results
Bacteriophage characteristics
The bacteriophages used in this study were character-
ized for their lytic activity against the target bacteria.
Accordingly, ECP311 belonged to Phieco32likevirus
(Podoviridae family) and has the adsorption velocity
of 1.1 × 10− 9 mL/min, latency period of 26 min and a
burst size of 180 phage particles/infected cell, KPP235
belonged to Podoviridae of phages with the adsorp-
tion velocity of 4.35 × 10− 9 mL/min, latent period of
40 min and a burst size of 120 phage particles/in-
fected cell while ELP140 belonged to Myoviridae and
has an adsorption velocity, latent period and burst
size of 2.8 × 10− 9 mL/min, 11 min and 135 phages/in-
fected cell (Additional file 1: Figure S1). ECP311 was
found to be lytic against 43 E. coli isolates that were
belonging to different pathotypes, KPP235 was lytic
against 17 different strains of K. pneumoniae and
ELP140 against 11 E. cloacae (n = 15), 2 E. hormae-
chei, 2 E. asburiae and 2 E. aerogenes isolates. In this
study only the host bacterial multi-drug resistant
strains, E. coli ec311, K. pneumoniae kp235 and E.
cloacae el140, against which these phages showed
maximum lytic activity were used (Additional file 2:
Table S1). The stability of these phages were tested at
different pH conditions by exposing them to varying
range of pH and the results showed that all the three
phage were viable from pH 3 to 11 and they are able
to show activity from 20 °C to 55 °C (data not
shown).
In vivo efficiency of phage treatment
All three phages (ECP311, KPP235 and ELP140) were
used for in vivo studies using G. mellonella (wax moth lar-
vae) model. The lethality of all the three bacteria against
the larvae was tested and the range 104 to 108 CFU/mL
was found to be highly lethal with all larvae dead within
48 h period at 108 CFU/mL (20 μL volume) concentra-
tions. Further experiments were performed using a bacter-
ial concentration of 108 CFU/mL. In the set of uninfected
and saline injected larvae used as a control 100% surviv-
ability obtained. The prepared phage lysate (104 PFU/mL)
was injected (20 μL) in another set of larvae and 100% sur-
vival rate was observed that showed the prepared phage
lysate for the treatment studies were not lethal to the lar-
vae even at higher doses. All the three above mentioned
groups were used as a control during the treatment
studies (Table 1). Prophylactic models were studied in
which larvae were infected with phages 2 h prior to their
infection with bacteria, but no observable differences in
survival rates were noted (data not shown).
For the single phage dose treatment, the bacterial in-
oculum (20 μL) of 108 CFU/mL and the phage titer
(20 μL) of 104 PFU/mL was used, and phages were
injected within 1 h of bacterial infection. The phage
treatment results were observed at 12, 24, 36, 48, 72 and
96 h. A single dose of ECP311 was found to be effective
for a 12 h period but the survivability of larvae reduced
at 24 h, 75% survival rate was observed with all larvae
dead within 96 h period (Fig. 1b). This data clearly
showed that more than one dose of phages may be
required to increase the survivability of larvae that were
infected with E. coli ec311. To prove this, multiple doses
of phages (104 PFU/mL) were given to the infected lar-
vae at 0th, 6th, 12th and 24th hours. The results showed
that at the single and double doses of phage treatment
(ECP311), the survival rate of larvae were 75% (Fig. 2a)
and increased bacterial load in the larvae were also ob-
served (Fig. 2a1). At the increased phage doses of three
and four, 100% survival rate and complete reduction of
bacterial load in the larvae was observed. This clearly
showed that in order to treat the larvae that were in-
fected with E. coli ec311 at least three doses of phages
are required at 6 h interval (Fig. 2a).
During the single dose KPP235 treatment (larvae were
infected with K. pneumoniae kp235), 100% survivability
was observed up to 96 h (Fig. 1c) but lesser movement
was noted in larvae after 72 h. Though, the single phage
dose treatment showed 100% survival rates, multiple
doses of phages were tested further. During the multiple
phage dose treatment, 100% survival rate and good
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larvae movement was observed up to 96 h after two
doses of phage treatment at 0thh and 6thh (Fig. 2b). Fur-
ther, to determine the bacterial load during the treat-
ment, sacrificed larvae were enumerated to analyze the
bacterial count and the data showed that after two phage
dose treatments, bacterial load was reduced and after
third and four doses there was no bacteria present in the
larvae (Fig. 2b1). The results showed that even the single
dose of phage treatment (KPP235) has a potential effect
against the K. pneumoniae kp235 infection though the
lethality of infection was found to be reduced only after
two doses of phage treatment (Fig. 2b, b1).
The ELP140 application on E. cloacae el140 infected lar-
vae showed that a single dose of phage is not sufficient to
obtain the 100% survival rate after 96 h. A single dose of
ELP140 was effective with a survival rate of 80% and
remained constant till 72 h with all larvae dead within
96 h period (Fig. 1d). After three doses of phage treatment
at 0th, 6th and 12th, complete reduction of bacterial
lethality was noted with 100% survival rate (Fig. 3a). A
reduction in bacterial load with the increase in number of
phage doses was also observed during the studies using
the larval samples (Fig. 3a1). In order to increase the larval
survivability during the phage treatment (ELP140), at least
three phage doses were required to treat the larvae that
were infected with E. cloacae el140.
To further study the potential of phage therapy against
the multiple bacterial infections, another set of studies
were performed using the larvae that were infected with
mixed bacterial culture (E. coli ec311, K. pneumoniae
kp235 and E. cloacae el140, 108 CFU/mL) and treated
using the phage cocktail (ECP311, KPP235 and ELP140
at 104 PFU/mL). When single dose of phage cocktail
treatment was used, Enterobacter cloacae was eliminated
completely but E. coli and K. pneumoniae were present,
which led to death of the larvae. To improve the effi-
ciency of phage cocktail treatment, multiple phage doses
up to five doses were used. The data showed that until
first three doses (0thh, 6thh and 12thh), there was only
60% survival rate and there was improvement in larval
survival after the fourth (24thh) and fifth (30thh) doses
(Fig. 3b). The bacterial load in larval fecal samples was
Table 1 Experiment setup to evaluate the efficiency of phage therapy for the treatment of G. mellonella using single phage dose,
multiple phage doses and phage cocktails
Regimen Model Treatment/condition
Control groups
SET 1 Control I (untreated) Larvae were injected with 20 μL of saline.
SET 2 Control II Larvae were infected with 20 μL of bacteria (108 CFU/mL).
SET 3 Control III Larvae were injected with 20 μL of phage lysate (104 PFU/mL).
Single Phage Dose
SET 4 Test-1 Larvae were infected with 20 μL of bacteria and treated with 20 μL
phages within 1 h.
Multiple Phage Doses
GROUP-1 Single dose Larvae were infected with 20 μL of bacteria and treated at 0th hour using
20 μL of phages.
GROUP-2 Double dose Larvae were infected with 20 μL of bacteria and treated with two doses
(20 μL each) of phages at 0th hour and at 6th hour.
GROUP-3 Triple dose Larvae were infected with 20 μL of bacteria and treated with three doses
(20 μL each) of phages at 0th hour, at 6th hour and 12th hours.
GROUP-4 Quadruple dose Larvae were infected with 20 μL of bacteria and treated with four doses
(20 μL each) of phages at 0th hour, at 6th, 12th and 24th hours.
Cocktail of Phages
GROUP-A Single cocktail dose Larvae were infected with 20 μL of bacterial mixture and treated
at 0th hour using 20 μL of phage cocktail.
GROUP-B Double cocktail dose Larvae were infected with 20 μL of bacterial mixture and treated
at 0th hour and at 6th hour using 20 μL of phage cocktail.
GROUP-C Triple cocktail dose Larvae were infected with 20 μL of bacterial mixture and treated
at 0th hour and at 6th, 12th hour using 20 μL of phage cocktail.
GROUP-D Quadruple cocktail dose Larvae were infected with 20 μL of bacterial mixture and treated
at 0th hour and at 6th, 12th, 24th hour using 20 μL of phage cocktail.
GROUP-E Quintuple cocktail dose Larvae were infected with 20 μL of bacterial mixture and treated
at 0th hour and at 6th, 12th, 24th, 30th hour using 20 μL of phage
cocktail.
*In each group 10 larvae were used for the study. For all the groups, the survivability of the larvae was evaluated for 96 h and the results were interpreted statistically
Manohar et al. BMC Microbiology  (2018) 18:97 Page 3 of 11
reduced only after four doses of phage (cocktail) treat-
ment (Fig. 3b1). This study showed that, for the applica-
tion of phage cocktail against the larvae infected with E.
coli ec311, K. pneumoniae kp235 and E. cloacae el140, a
single dose of phage cocktail was found to be less effect-
ive but four doses of phage cocktail was very effective
and sufficient to produce 100% survival rates in larvae
model.
Discussion
Phages have wide applications and can be used as
biocontrol agents in food processing to reduce the
bacterial load [13], or to treat bacterial infections in
food animals or in eliminating the bacterial pathogens
in crops [14–16]. Phage therapy is developing as a
promising treatment of choice to cure infections
caused by multi-drug resistant bacteria and there are
increasing reports on the bacteriophages that are iso-
lated against pathogens such as E. coli, K. pneumo-
niae and E. cloacae [17–20].
The three phages used in this study, Escherichia phage
ECP311, Klebsiella phage KP235 and Enterobacter phage
ELP140 showed 100% lytic activity against E. coli, K.
pneumoniae and E. cloacae when tested in vitro. Hence,
the activity of phages in vivo was examined using G.
mellonella as a model organism. Initial bacterial viru-
lence studies showed that the test bacterial pathogens
(E. coli, K. pneumoniae and E. cloacae) were highly lethal
to the larvae and were dead within 48 h at the bacterial
load of 108 CFU/mL. A single phage dose (ECP311,
KPP235 and ELP140) was found to increase the survival
rate of larvae that were infected with bacteria. In the
course of the experiment, when single phage dose was
used for the treatment, there was a gradual decrease in
phage count which subsequently led to the recovery and
multiplication of bacteria causing death of the larvae. A
similar result was observed by Olszak et al. when
PB1-like phage was injected to treat larvae that were in-
fected with P. aeruginosa [21]. When multiple phage
doses were used to treat larvae infection, three doses of
phage injection at 0thh, 6thh and 12thh was found to be
sufficient to obtain 100% survival rate and complete re-
duction of bacterial load in larvae was observed in this
study. Dosage dependent survival rates was observed in
Fig. 1 Impact of single dose phage treatment on E. coli ec311, K. pneumoniae kp235 and E. cloacae el140 infection and survival rates of G.
mellonella larvae. A single phage dose (104 PFU/mL) was injected at 0th hour after the larvae was pre-infected with 108 CFU/mL of bacteria.
a Saline, phage and bacteria only control group larval survival. b Survival rates of the larvae infected with E. coli ec311 treated with single dose of
Escherichia phage ECP311 (p = 0.0045). c Survival rates of the larvae infected with K. pneumoniae kp235 treated with single dose Klebsiella phage
KPP235 (p = 0.0006). d Survival rates of larvae infected with E. cloacae el140 treated with Enterobacter phage ELP140 (p = 0.0052). The survival rates
were plotted using the Kaplan-Meier method and log-rank test was used to analyze the difference in survival rates in GraphPad Prism 7.0. All
phage treatment results were compared with the control. A statistically significant difference (p < 0.05) was observed using 10 worms per group
on phage treatment
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the larvae which showed that even though phages are
considered to have auto-dosing, there is a need for
minimal dosage to remove the pathogen. In this
study, both Escherichia phage ECP311 and Enterobac-
ter phage ELP140 were found to be less effective dur-
ing the single phage dose treatment of infected larvae
but the Klebsiella phage KPP235 was found to in-
crease the survival rate even at single phage dose.
Earlier studies showed the importance of phage size
and phage generation time that can influence the
therapeutic results of phage therapy [21]. The three
phages used in this study Escherichia phage ECP311;
Klebsiella phage KPP235 and Enterobacter phage
ELP140 belonged to Podoviridae and Myoviridae
families respectively. The Klebsiella phage KPP235
which was effective with single phage dose treatment
Fig. 2 Impact of multiple phage doses on survivability of larvae that was infected with E. coli ec311 and K. pneumoniae kp235. The multiple
phage doses (104 PFU/mL) were injected at 0th, 6th, 12th and 24th hour after the larvae were pre-infected with 108 CFU/mL of bacteria. All the
phage treatment results were compared with the control. a Impact of multiple doses of Escherichia phage ECP311 on the survivability of larvae
infected with E. coli ec311 (p = 0.0002). a1 Bacterial enumeration from larvae, results are represented as CFU of bacteria/larva. b Impact of multiple
doses of Klebsiella phage KPP235 on the survivability of larvae infected with K. pneumoniae kp235 (p = 0.0001). b1 Bacterial enumerations from
larvae, results are represented as CFU of bacteria/larva. The survival rates were plotted using the Kaplan-Meier method and log-rank test was used
to analyze the difference in survival rates. A statistically significant difference (p < 0.05) was observed using 10 worms per group on phage
treatment. Error bars represent standard error of the mean (SEM) of three independent replicates and data were analyzed using GraphPad
Prism 7.0
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belonged to Podoviridae having a life cycle with an ad-
sorption velocity of 4.35 × 10− 9 mL/min, latent period of
40 min and a burst size of 120 phage particles/infected
cell. Enterobacter phage ELP140 was found to have a
shorter life cycle with an adsorption velocity of 2.8 × 10− 9,
11 min latency period with the release of 135 phages/
infected cell, and Escherichia phage ECP311 having a life
cycle with an adsorption velocity of 1.1 × 10− 9, 26 min
latency period with the release of 110 phages/infected cell.
The latter two phages ELP140 and ECP311 required more
than a single dose for recovering larvae from bacterial
infection.
Fig. 3 Impact of multiple phage doses on survivability of larvae that was infected with E. cloacae el140 and the efficiency of phage cocktail in
treating multiple bacterial infections. The multiple doses of phages (104 PFU/mL) were injected at 0th, 6th, 12th, 24th and 30th hour after the larvae
was pre-infected with 108 CFU/mL of bacteria. All the phage treatment results were compared with the control. a Impact of multiple doses of
Enterobacter phage ELP140 on the survivability of larvae infected with E. cloacae el140 (p = 0.0003). a1 Bacterial enumeration from larvae, results
are represented as CFU of bacteria/larva. b Phage cocktail studies- Impact of multiple doses of phage cocktail on the survivability of larvae
infected with mixed bacteria (E. coli ec311, K. pneumoniae kp235 and E. cloacae el140), for the phage cocktail studies five doses of prepared
phage cocktail was used and the results are represented as time to death (p = 0.0016). b1) Phage cocktail studies- Bacterial enumeration from
larvae after the experiment. Results are represented as CFU of bacteria/larva. The survival rates were plotted using the Kaplan-Meier method and
log-rank test was used to analyze the difference in survival rates. A statistically significant difference (p < 0.05) was observed using 10 worms per
group on phage treatment. Error bars represent standard error of the mean (SEM) of three independent replicates and data were analyzed using
GraphPad Prism 7.0
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The application of multiple phage doses to elimin-
ate the bacteria (pathogen) from the larvae could also
prove that the use of single phage (instead of cocktail
of phages) should be sufficient to achieve the 100%
survival rate when targeting the single bacterial infec-
tions. But earlier studies showed the use of cocktail
of phages to eliminate the bacterial infection [21, 22].
This study shows that the effectiveness of phage ther-
apy depends only of the ability of single phage to re-
duce the bacterial load and not on the complexity of
phage preparations. This study also highlights the use
of phage cocktails in eliminating the multiple bacter-
ial infections which showed 100% survival rate of lar-
vae with four doses of prepared phage cocktails. To
the best of our knowledge, this is the first study to
report the use of phage cocktails to cure multiple
bacterial infections in G. mellonella larvae model. The
data obtained from phage cocktail studies clearly
showed that the phages can act synergistically to
eliminate the bacterial infection. Our study reports
the efficiency of phage cocktail against multiple/mixed
bacterial infections. The studies using phage cocktails
are complicated in their application because four/five
continuous phage dose (at 6 h interval) are required
to achieve 100% survival rate, so during therapy con-
tinuous monitoring of patient, immune complexity
and effectiveness of patient should be carefully exam-
ined. Further, thorough investigation on phage cock-
tail will help in improving the clinical outcome of
phage therapy and in treatment of patients infected
with multiple pathogenic strains of bacteria. The
route of administration of phages was found to have
a profound effect on therapeutic outcome of the pa-
tients [18, 21, 23]. In some cases, a single phage dose
treatment was not only found to be less effective but
it also worsened the larval condition when tested for
more than 72 h. The reason may be due to the rapid
release of lipopolysaccharides (LPS) during the com-
pound bacterial killing that causing deteriorated ani-
mal health [21, 24]. In order to avoid this during
phage therapy, the use of single complex dose of
phages should be avoided so that the side effects during
bactericidal application and due to toxicity can be elimi-
nated. The use of bacteriophage cocktail was found to ef-
fective in the treatment of Acinetobacter baumannii
infection which saw the administration of bacteriophages
intravenously and percutaneous into the abscess cavities,
led to the reversal of the patient’s deteriorating clinical
outcome, clearing all infection and return to health [25].
The treatment of Gram-negative bacterial infections is
more complicated because the administration of any
bacteriolytic agents can result in inflammatory responses
(syndrome) due to toxic release; thus the choice of
therapy/administration should be selected carefully.
Conclusion
In this study, the route of administration of phages to
the larvae was by intrahemocoelic (injection in to the
last left pro-leg) which is comparable to the intravenous
mode of administration in vertebrates. Considerably, the
studied phages will have profound effect on vertebrates
when they are used intravenously. Though our study
showed some promising results for the studied phages
using a simple animal model (wax moth larvae), a more
detailed study is required to understand the dynamic re-
lation of bacteriophages with the host bacterium and the
various factors that govern this before any clinical trials
are performed. In this study, we found that a single
phage dose is enough to abolish the lethality (90% sur-
vival) of all the three bacterial infections in vivo, but to
obtain 100% survival rate at least three phage doses are
required at 6 h interval. For the first time, our study
showed 100% survival of in vivo animal models when
phage cocktail is used against mixed bacterial infections.
This study had proven that a simple animal model like
wax moth larvae is sufficient to evaluate the preliminary
outcome of phage therapy. Future work should be
considered using the phages against broader bacterial
hosts and efficiency of treatment must be tested in more
complex animal models.
Methods
Bacterial isolates and bacteriophages
A total of three multi-drug resistant Gram-negative
bacteria Escherichia coli ec311, Klebsiella pneumoniae
kp235 and Enterobacter cloacae el140 collected from
diagnostic centers in Tamil Nadu, India were examined
in this study. The bacterial identification was performed
using VITEK identification system and 16S rRNA
analysis. All three bacterial isolates were found to be
resistant to ampicillin, cefotaxime, cefepime, gentamycin,
amoxyclav, carbapenem and colistin. Bacteriophages
were isolated from sewage treatment plants and initial
screen showed that they had a broad host-range activity
and were stable. The phages were named as Escherichia
phage ECP311 (ECP311), Klebsiella phage KPP235
(KPP235) and Enterobacter phage ELP140 (ELP140).
The invitro lytic activity data and one-step growth curves
of the three phages are depicted in Additional file 2:
Table S1 and Additional file 1: Figure S1 respectively.
In vitro phage activity
For testing in vitro phage activity; spot test, phage
plaque assay and broth propagation assay were
performed as described earlier [17]. I) The bacterial lawn
culture was prepared in Luria Bertani (LB) agar plate
and 10 μL of respective phage lysate was spotted. The
plates were incubated for 8 h and the appearance of bac-
terial clearance zone on the spots indicated the phage
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lytic activity. II) For phage plaque assay, 400 μL of
bacterial culture (O.D600 = 0.65) was mixed with 200 μL
of phage lysate and incubated at 37 °C for 10–15 min.
The preparation was added to 3 mL of molten soft agar
(0.75%) and mixed well and poured on solidified LB agar
plates. The plates were allowed to solidify and incubated
at 37 °C for 12 h and plaques were estimated. III) In the
broth propagation assay, 50 μL of phage lysate was
added to the 100 mL of bacterial inoculum. From the
mixture, 100 μL was removed for every 2 h and 1:10
dilution was spread on LB agar plate. The plates were
examined for reduction in bacterial count for 12 h at 2 h
interval. Multiplicity of Infection (MOI) was calculated
as the number of phage particles (PFU) divided by the
number of bacterial cells (CFU). The stability of these
phages was tested at different pH conditions by exposing
the phages in the varying pH buffers ranging from 1 to
14 and at temperatures up to 70 °C.
In vivo studies - G. Mellonella as an infection model
For in vivo studies, Galleria mellonella were used, the
moths were obtained from Department of Entomology,
University of Agricultural Sciences, Gandhi Krishi
Vignana Kendra, Bengaluru, India. The moths were re-
ceived at their young larval stage (app. 5 mm in length)
and grown using artificial food (Corn meal: 400 g,
Wheat flour: 200 g, Milk powder: 200 g, Yeast tablets:
100 g, Honey: 400 ml, Glycerin: 300 ml) at 35 °C in
Antibiotic Resistance and Phage Therapy Laboratory,
VIT, Vellore, India. Once the worms reached their late
larval stage (app. 2–2.5 cm, creamy white color), they
were used for evaluating the potential of bacteriophages
(Abedon et al. 2017). After the study, G. mellonella
health index scoring was performed using the larvae
survival as categorized by either alive or dead. The larvae
were considered as dead only when there was no 7move-
ment or minimal movement on stimulation or larva
appearing black (melanization) or > 3 black spots on
brown larvae (Abedon et al. 2017), and considered alive
only when there was movement without stimulation and
no melanization (Fig. 4).
Phage treatment: In vivo assays
Briefly, the host bacteria of E. coli ec311, K. pneumoniae
kp235 and E. cloacae el140, were grown overnight and
centrifuged at 8000 × g for 15 min. The resultant pellet
was diluted to obtain the required 108 CFU/mL (approx.
O.D600 of 0.65) using LB broth and 20 μL of culture was
used for infecting G. mellonella. The larvae were starved
for 24 h before the experiment and both the bacterium
and phage lysate was injected into the larva through the
last left pro-leg. A set of 10 larvae per group was used.
The study was conducted using three controls (Fig. 5); a)
in set-1 all the larvae were injected with 20 μL of saline.
b) in set-2 all the larvae were infected with 20 μL of
bacterial inoculum and larval survivability was tested. c)
in set-3 all the larvae were injected with 20 μL of pre-
pared phage lysate and survivability was evaluated, d)
set-4 (test), all the larvae were injected with bacterial in-
oculum (108 CFU/mL) and treated with respective phage
lysate (104 PFU/mL). For assessing the antibacterial ac-
tivity of phages in set-4, 20 μL of bacterial suspension
was injected and within 1 h 20 μL of phage lysate was
injected (for single phage dose). The larvae were tested
for their survival at 12, 24, 48, 72 and 96 h, and the
results were expressed as percentage survival. To deter-
mine the effect of multiple phage doses on larvae sur-
vival, four groups were maintained; once the larvae were
infected with bacteria, the first phage dose was received
at 0 h (group A-1 dose at 0 h), the second dose at 6 h
(group B-2 doses at 0 h and 6 h), the third dose at 12 h
(group C-3 doses at 0 h, 6 h and 12 h) and the fourth
dose at 24 h (group D-4 doses at 0 h, 6 h, 12 h and
24 h). The treated larvae were evaluated for their sur-
vival at every 12 h up to 96 h and the bacterial enumer-
ation from dead and live larvae was performed on LB
agar by plating 0.1 mL of homogenized sample using the
serial dilution method and the bacterial load of CFU per
larva was enumerated. Five larvae from each group were
examined and all the experiments were performed in
triplicates and analysed using GraphPad Prism 7.0.
Cocktail of phages against G. mellonella multiple bacterial
infection
Larvae (n = 10) were infected with mixed bacterial
culture (three bacteria at equal concentration each at
108 CFU/mL) and treated using the phage cocktail (three
phages at equal concentration each at 104 PFU/mL). The
prepared bacterial inoculum was mixed in the equal vol-
ume (100 μL each) and 20 μL from the mixed suspen-
sion was injected into the larvae. The infected larvae
were treated using the prepared phage cocktail (20 μL)
using a single dose (at 0 h), and with multiple doses;
after 0 h (group-A- 1 dose), after 0 h and 6 h (group B-
2 doses), after 0 h, 6 h and 12 h (group C- 3 doses), after
0 h, 6 h, 12 h and 24 h (group-D 4 doses) and after 0 h,
6 h, 12 h, 24 h and 30 h (group E- 5 doses). The surviv-
ability was assessed at every 12 h up to 96 h and the re-
sults were interpreted as the percentage survival rates.
All the experiments were performed in triplicates. The
bacterial enumeration from dead and live larvae was per-
formed on LB agar by plating 0.1 mL of homogenized
sample using the serial dilution method and the bacterial
load (CFU per larva) was enumerated. Five larvae from
each group were examined and all the experiments were
performed in triplicates and analysed using GraphPad
Prism 7.0.
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Fig. 5 Diagrammatic representation of experiment setup used to evaluate the efficiency of phage therapy for the treatment of G. mellonella using
single phage dose and multiple phage doses
Fig. 4 Morphology of G. mellonella used for the study, impact of phage treatment and the effect of bacterial infection. a Larva injected with
saline (used as a control), b Larva survived after phage treatment, c Larva infected with bacteria, representation of different melanization observed
on larvae, d Larva infected with bacteria alone (used as a control). The worms appearing black (melanization) or no movement were considered
as dead and the worms that had movement without stimulation or no melanization were considered as alive
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Statistical analyses
The survival curves were plotted using Kaplan-Meier
method and log-rank test was used to calculate the
difference in survival rates using GraphPad Prism
software 7.0 (GraphPad Software, Inc., La Jolla, USA).
p < 0.05 was considered as statistically significant.
Additional files
Additional file 1: Figure S1. One-step growth experiment results for
the three phages: A) E. coli ec311, B) K. pneumoniae kp235, and
C) E. cloacae el140. (DOCX 94 kb)
Additional file 2: Table S1. Host-range infection of the phages,
Escherichia phage ECP311 (ECP311), Klebsiella phage KPP235 (KPP235)
and Enterobacter phage ELP140 (ELP140). (DOCX 16 kb)
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